GE Healthcare is marking its territory in the cell therapy market with the recent acquisition of Biosafe Group SA, a supplier of cell processing systems.
Biosafe, headquartered in Switzerland, is a veteran in the field of bioprocessing, regenerative medicine and stem cell banking.
A GE spokesperson said the company will gain 85 new employees and about 230 customers through the acquisition to double GE's cell therapy staff and sales, according to a Reuters report.
"GE is building a world-class set of tools, technologies and services for cell and gene therapy and Biosafe’s expertise and innovative systems will strongly enhance our customer offering," said Kieran Murphy, CEO of Life Sciences for England-based GE Healthcare.
More articles on supply chain:
10 costliest medical conditions
FDA Commissioner: US needs improved system to track medical device issues
This liquid is painted on cavities to stop tooth decay